Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | NAAA | Q02083 | 1/20 | 0.53 |
| ▸ | IDO1 | P14902 | 1/20 | 0.48 |
| ▸ | AGXT | P21549 | 1/20 | 0.46 |
| ▸ | LTA4H | P09960 | 2/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.45 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | TACR1 | P25103 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6554989 | 1.00 | TSHR (0.58) | TSHRNAAAIDO1AGXTLTA4H | |
| SCHEMBL4454168 | 1.00 | TSHR (0.58) | TSHRNAAAIDO1AGXTLTA4H | |
| SCHEMBL12013285 | 1.00 | TSHR (0.58) | TSHRNAAAIDO1AGXTLTA4H | |
| SCHEMBL13671100 | 1.00 | TSHR (0.58) | TSHRNAAAIDO1AGXTLTA4H | |
| SCHEMBL12020781 | 1.00 | TSHR (0.58) | TSHRNAAAIDO1AGXTLTA4H | |
| SCHEMBL25227691 | 1.00 | TSHR (0.58) | TSHRNAAAIDO1AGXTLTA4H | |
| SCHEMBL2794 | 0.96 | TSHR (0.64) | TSHRNAAAIDO1AGXTLTA4H | |
| SCHEMBL21214934 | 0.94 | TSHR (0.52) | TSHRNAAAIDO1AGXTLTA4H | |
| SCHEMBL9761302 | 0.94 | TSHR (0.52) | TSHRNAAAIDO1AGXTLTA4H | |
| Hydrochloric Acid SCHEMBL3232897 | 0.93 | TSHR (0.61) | TSHRNAAAIDO1AGXTLTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7598421-B2 | Materials for the delivery of biologically-active material to cells | UCL BIOMEDICA PLC (GB) | 2009-10-06 | — | — | US | disclosed |
| US-7598421-B2 | Materials for the delivery of biologically-active material to cells | UCL BIOMEDICA PLC (GB) | 2009-10-06 | — | — | US | disclosed |
| WO-2005117985-A2 | LIPOPOLYPLEX CONSTRUCT WITH AN INTEGRIN BINDING PEPTIDE FOR DELIVERY OF NUCLEIC ACIDS, PEPTIDES OR DRUGS | UCL BIOMEDICA PLC (GB) | 2005-12-15 | — | — | WO | disclosed |
| US-20050245446-A1 | Materials for the delivery of biologically-active material to cells | NANOGENICS LIMITED (GB) | 2005-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245446-A1 | Materials for the delivery of biologically-active material to cells | ITGB1, ITGA2B, ITGB2 | TSHR 616/4885NAAA 4315/4885IDO1 4817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.